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Abstract Here we describe the construction of recombinant
adenoviruses expressing dopamine D2 and D4 receptors, and
their ability to mediate high levels of heterologous expression in a
variety of cell types in vitro and in vivo for at least 7 days post
infection. These experiments demonstrated that maximum
receptor expression is achieved generally within 24 h and remains
constant thereafter. Maximum expression levels were highly
variable between cell lines and dependent on infection efficiency
and promoter strength. Correction for these two variables
revealed differences in relative expression levels between cell
lines varying by two orders of magnitude. Our results indicate
that in addition to gene transcription, post-transcriptional
mechanisms play a dominant role in determining dopamine
receptor levels in this system.
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1. Introduction
In its simplest form receptor expression levels are the result
of de novo synthesis and protein degradation. There is an
increased understanding of several aspects of these processes
and how they are altered in response to receptor activation,
but it is less clear to what extent di¡erent cellular processes
modulate steady-state levels of G protein-coupled receptors
[1^10]. To our knowledge there are no reports that have pro-
vided information on the relative contribution of the sum of
all post-transcriptional processes in steady-state level receptor
expression. In general it is assumed that the level of activation
of the genes for G protein-coupled receptors are the predom-
inant factors in receptor expression and that the various post-
transcriptional processes play a modulatory role in receptor
expression [7,11^16].
We examined cell-speci¢c dopamine receptor expression by
e⁄ciently introducing the G protein-coupled dopamine D2
and D4 receptors in a controlled manner into a variety of
cell lines. Subsequent evaluation of steady-state receptor levels
in relation to gene expression mediated by the constitutively
active Rous sarcoma virus long terminal repeat promoter en-
hancer (RSV-LTR) and e⁄ciency of delivery of the expression
vector allowed for the comparison of the relative contribution
of these di¡erent processes to receptor expression.
To achieve an e⁄cient and controlled delivery of the dop-
amine receptor expression cassettes in a wide host range of
cells, we used a recombinant adenovirus. Type 5 adenoviruses
have been successfully used to transfer several di¡erent trans-
genes, both in vitro and in vivo, to a wide host range of
replicating and non-replicating cells [17], including the dop-
amine D2 receptor [18,19].
In this study, we created ¢rst generation recombinant ad-
enoviral vectors expressing either the D2 or D4 dopamine
receptors. The recombinant vectors were characterized in a
variety of cell lines and in rat brain with respect to their
ability to induce dopamine receptor expression. We demon-
strate that recombinant adenoviruses are excellent viral vec-
tors for expressing dopamine receptors in vitro and in vivo.
Further, the recombinant vectors mediate receptor expression
in many, but not all cell types. Receptor expression is not only
dependent on infectivity and promoter strength, but is highly
dependent on post-translational events that vary strongly be-
tween di¡erent cell lines.
2. Materials and methods
2.1. Cell culture
CHO-K1 cells (ATCC, Rockville, MD) were grown in K-MEM
supplemented with 2.5% fetal bovine serum and 2.5% horse serum
(Gibco BRL). HEK-293, COS-7, mouse Ltk3, and HeLa cells
(ATCC, Rockville, MD) were grown in K-MEM supplemented with
10% FBS. GH4-C1 and SKNMC cells were cultured in Ham’s F10
medium supplemented with 8% FBS.
2.2. Recombinant adenoviruses
First generation recombinant adenoviruses expressing the dopamine
D2 (AdRSVD2), D4.4 (AdRSVD4.4) and the ¢re£y luciferase gene
(AdRSVLuc) under control of the RSV-LTR promoter were con-
structed as previously described [20]. Brie£y, the shuttle plasmid
pXCJL-2, containing the transgene of interest, was cotransfected
with the plasmid pJM17 into HEK-293 cells and overlaid with agar-
ose (plasmids pXCJL-2 and pJM17 were a kind gift of Dr. F. Gra-
ham, McMaster University, Hamilton, Ont.). Plaques were picked,
veri¢ed by restriction digestion and subjected to plaque puri¢cation
followed by two rounds of CsCl density ultracentrifugation. Virus was
dialyzed using a Pierce Dialysis Cassette (Pierce) and viral stocks were
aliquoted and stored at 370‡C. Titers were determined with a HEK-
293 plaque assay. Stocks were assayed for wild type adenoviruses
using HeLa plaque assays and PCR with E1 speci¢c primers [21,22].
2.3. Histochemical L-galactosidase staining
Recombinant adenovirus expressing the L-galactosidase gene under
control of the CMV promoter (AdCMVLacZ, a gift from Dr. F.
Graham, McMaster University, Hamilton, Ont.) were detected by
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histochemical staining using X-Gal. To detect L-galactosidase, culture
medium was aspirated and the cells were ¢xed with 2% formaldehyde/
0.2% glutaraldehyde (10 min at room temperature), followed by stain-
ing with X-Gal staining solution (100 mM sodium phosphate, 1.3 mM
MgCl2, 3 mM K3Fe(CN)6, 3 mM K4Fe(CN)6, and 1 mg/ml X-Gal) at
37‡C, overnight.
Analysis of L-galactosidase expression in brain tissue was done on
cryostat sections (20 Wm thickness) from frozen rat brain. Sections
were placed on glycerine-coated slides, and dried. Brain slices were
¢xed in 2% paraformaldehyde/0.2% glutaraldehyde at 4‡C for 15 min,
and then stained with X-Gal solution at 37‡C overnight.
2.4. Luciferase assays
Luciferase assays were done as described previously [23]. Lysate of
infected cells (200 Wl) was combined with 15 Wl of luciferase cocktail
(750 nM Tris/MES, pH 7.8; 15 mM MgOAc and 40 mM ATP) in
plastic cuvettes and loaded into a luminometer (BioOrbit 1250, Phar-
macia) where 200 Wl of 1 mM luciferin dissolved in 5 mM potassium
phosphate, pH 7.5 was automatically dispensed. Peak light emission
was recorded by a chart recorder.
2.5. Ligand binding analysis
Infected cells were collected and homogenized at 4‡C in binding
bu¡er (50 mM Tris-HCl, pH 7.4, 5 mM EDTA, 1.5 mM CaCl2,
5 mM KCl and 120 mM NaCl). Homogenates were centrifuged at
39 000Ug for 15 min and the pellets were resuspended in binding
bu¡er at a concentration of 1 mg/ml. For saturation binding analysis,
500 Wl of homogenate was incubated in duplicate with increasing
concentrations (10^1000 pM) of [3H]spiperone (120 WCi/mmol). For
competition binding analysis, 200^250 pM [3H]spiperone was co-in-
cubated with increasing concentrations (10^1000 pM) of competing
ligands (in duplicate), either in the presence or in the absence of 200
WM Gpp(NH)p. Non-speci¢c binding was determined by co-incuba-
tion of [3H]spiperone with 30 WM of dopamine or 10 WM of butacla-
mol. The samples were incubated in a ¢nal volume of 1.5 ml for 2 h at
room temperature and ¢ltered using a cell harvester (Skatron Instru-
ments, Norway) and counted by liquid scintillation counting. All
binding experiments were done in duplicate or triplicate. Densities
(Bmax) and the dissociation constants (Kd) of the various ligands
were determined by Scatchard analysis. Ligand binding data were
analyzed using the non-linear least-square curve-¢tting program
LIGAND. Soluble protein concentrations were determined by the
Bradford method [24].
2.6. Measurement of intracellular cyclic AMP levels
CHO-K1 cells were plated on 6-well plates 1 day prior to infection,
and infected at a multiplicity of infection (moi) of 100. One day later,
cells were washed once with phosphate bu¡ered saline (PBS) followed
by a wash with 1 ml of HBBS/well (118 mM NaCl, 4.6 mM KCl,
1 mM CaCl2, 1 mM MgCl2, 10 mM D-glucose, 20 mM HEPES and
0.3 mM isobutyl-1-methyl-xanthine (IBMX), pH 7.2). Cells were
stimulated with 10 WM of forskolin and incubated with various con-
centrations of dopamine and quinpirole ranging from 0.1 pM to
100 WM. Cells were incubated for 20 min at 37‡C in a ¢nal volume
of 1 ml and then harvested i n 1ml of permeabilization bu¡er (0.05%
(v/v) Triton X-100 in HBBS bu¡er). Samples were vortexed and cen-
trifuged for 5 min at 13 000 rpm and the supernatant was collected
and frozen at 380‡C for cAMP measurement by radioimmunoassay
(RIA). The experiments described were done in triplicate.
2.7. cAMP radioimmunoassays
Measurement of intracellular cAMP levels was performed as de-
scribed previously using a cyclic AMP speci¢c antiserum (Sigma)[25].
The cAMP RIAs were performed in triplicate for each experiment.
2.8. Infection of cell lines and rat brain tissue
For expression studies in cell lines, medium was aspirated from 150
mm plates. 15 ml of medium containing recombinant adenovirus at
the appropriate moi was added to the cells. The cells were incubated
for 24 h at 37‡C (5% CO2). Next, the infection medium was removed,
cells were rinsed with PBS and medium was added. This point in time
of the experimental protocol was de¢ned as time zero post infection.
Microinjection of recombinant adenovirus into brain tissue was
performed using standard stereotactic neurosurgical procedures,
under anesthesia with a single injection of sodium pentobarbital (55
mg/kg i.p.), and buprenorphine (0.01^0.05 mg/kg). The animals were
then placed in a stereotactic frame (KOPF 900-David Kopf Instru-
ments, CA). At the chosen coordinates (Paxinos and Watson, 1986) a
small opening was drilled in the skull to permit insertion of a ¢ne (32
gauge) injection needle, connected to a 10 Wl Hamilton syringe con-
taining the viral preparation. Each injection consists of a single in-
jection of 1^5 Wl (109^1010 plaque forming units (pfu)/ml)) injected
over a 5^15 min interval using an automated delivery system (Razel
Syringe Pump, Razel Scienti¢c Instruments). The needle was with-
drawn slowly over 30 s, the skull defect ¢lled with bone wax, and
the scalp sutured.
2.9. Autoradiography of dopamine receptors in rat brain
D2-like receptors were detected by autoradiography using
[3H]spiperone (200 pM) (Amersham Life Science) [26]. Non-speci¢c
binding was determined by inclusion of 200 nM haloperidol. Slides
were pre-incubated in bu¡er (50 mM HEPES, 1 mM EDTA, 5 mM
KCl, 1.5 mM CaCl2, 4 mM MgCl2, 120 mM NaCl) for 30 min, and
then immersed in bu¡er containing [3H]spiperone for 2 h at 20‡C.
Next, the slides were washed twice for 5 min with pre-incubation
bu¡er at 4‡C, followed by a rinse with distilled water at 4‡C, and
dried. The slides were exposed to X-ray ¢lm (3H Hyper¢lm, Amer-
sham Life Science) for 2^3 weeks. Relative optical density (ROD) of
the autoradiographic signals was measured by image analysis as de-
scribed previously [26].
3. Results
3.1. Pharmacological analysis of D2 and D4 expressing
recombinant adenovirus
Competition binding analyses were performed in CHO-K1
cells infected at an moi of 100 with either the AdRSVD2 or
AdRSVD4.4 adenoviruses. The results of these studies are
listed in Table 1 and demonstrate the appropriate rank order
of a⁄nity for the di¡erent ligands for the receptors [27]. The
agonists, dopamine and quinpirole, bound with high a⁄nity
to the D4 receptor. Inclusion of the non-hydrolyzable GTP
analogue Gpp[NH]p in the binding assay lowered the a⁄nity
for agonists. D2 receptors bound the agonists only with low
a⁄nity that was insensitive to the addition of Gpp[NH]p.
Saturation binding analysis of the di¡erent cell lines (CHO-
K1, COS-7, HeLa, SKNMC and GH4-C1) infected with these
viruses demonstrated that D2 and D4.4 (as well as D4.2 and
D4.7 isoforms; data not shown) bound [3H]spiperone with an
a⁄nity of about 75 pM and 150 pM, respectively. Infection of
the di¡erent cell lines with AdRSVLuc did not result in de-
tectable [3H]spiperone binding.
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Table 1
Pharmacological analysis of dopamine D2 and D4.4 receptors ex-
pressed by adenoviral vectors in CHO-K1 cells
A⁄nity (Ki) (nM)
AdRSVD2 AdRSVD4.4
Nemonapride 0.1 0.1
Haloperidol 1.4 0.9
Raclopride 43 3400
Clozapine 444 14
Dopamine s 5000 8.2
Dopamine+G s 5000 21.0
Quinpirole s 2000 5.0
Quinpirole+G s 2000 12.4
Competition binding analysis of various dopamine receptor ligands,
using [3H]spiperone, for dopamine D2 and D4.4 receptors expressed
in CHO-K1 cells with the adenoviral vectors AdRSVD2 and
AdRSVD4.4, respectively. The average a⁄nities (Ki) were calculated
with the non-linear least-square curve ¢tting program LIGAND.
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3.2. Functional analysis of D2 and D4 expressing recombinant
adenovirus
Functional studies were performed in parallel with satura-
tion and competition binding analyses in CHO-K1 cells in-
fected with either AdRSVD2 or AdRSVD4.4 at an moi of
100. Fig. 1 illustrates the results of our functional assays
measuring the inhibition of forskolin-stimulated cAMP accu-
mulation via either the D2 or D4 receptors in the presence of
di¡erent concentrations of the agonists dopamine or quinpir-
ole. The percentage inhibition of forskolin-stimulated cAMP
levels in the CHO-K1 infected cells was about 90% for both
D2 and D4 receptors. The EC50 for dopamine and quinpirole
was 20^80 nM.
3.3. Adenoviral-mediated dopamine receptor expression in vitro
and in vivo
To explore the host range and factors that modulate the
expression levels of the dopamine receptors various estab-
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Fig. 1. Inhibition of forskolin-stimulated cAMP levels by dopamine and quinpirole of CHO-K1 cells infected with the adenoviral dopamine D2
and D4 expression vectors AdRSVD2 and AdRSVD4.4, respectively. The percentage inhibition is standardized by setting forskolin-stimulated
cAMP levels at 100% and maximal inhibition by dopamine at 0%. The percentage of inhibition by dopamine was on average 90%. The curves
presented are a composite of at least nine independent experiments in which the individual points of the experiments are given as the mean þ
S.E.M. The EC50 displayed is the mean of values obtained from the individual experiments.
Fig. 2. Infectivity and expression of the adenoviral L-galactosidase and luciferase expression vectors AdCMVLacZ and AdRSVLuc in di¡erent
cell lines. The left panel depicts the relationship between multiplicity of infection and percentage of L-galactosidase (LacZ) expressing cells of
di¡erent cell lines infected with AdCMVLacZ. The right panel shows the relationship between multiplicity of infection and luciferase activity
for the di¡erent cell lines infected with AdRSVLuc. The individual points in the graphs represent the average of at least ¢ve independent ex-
periments.
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Fig. 3. Relationship between dopamine D2 receptor expression and time post infection with AdRSVD2 at moi of 1 (A), 10 (B), 100 (C). The
relationship between receptor expression independent from promoter-mediated expression (Bmax/relative luciferase activity (RLU)) and time at
moi with equivalent infection rates (75^90%) is shown in D. The individual data points in the graphs are the average densities determined by a
12 point Scatchard plot performed in duplicate from at least two independent experiments.
Fig. 4. Relationship between dopamine D4 receptor expression and time post-infection with AdRSVD4.4 at moi of 1 (A), 10 (B), 100 (C). The
relationship between receptor expression independent from promoter-mediated expression (Bmax/relative luciferase activity (RLU)) and time at
moi with equivalent infection rates (75^90%) is shown in D. The individual data points in the graphs are the average densities determined by a
12 point Scatchard plot performed in duplicate from at least two independent experiments.
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lished cell lines (Figs. 2^4) and brain tissues (Fig. 5) were
infected with AdRSVD2, AdRSVD4.4, AdRSVLuc and
AdCMVLacZ. Saturation binding and Scatchard analyses
were performed on CHO-K1, COS-7, HeLa, SK-N-MC and
GH4-C1 cell lines infected with AdRSVD2 or AdRSVD4.4 at
moi of 1, 10 and 100. Receptor density measurements (Bmax)
for each receptor at post-infection times of 1, 3 and 5 days are
presented in Figs. 3 and 4. We observed an almost linear
relationship between moi and receptor density. Maximum re-
ceptor density is reached in most experiments within 24 h post
infection. Both D2 and D4 receptors were expressed at highest
levels in GH4-C1 and SKNMC cells. Even higher levels of
expression can be detected in HEK293 cells (V50 pmol/mg
protein; data not shown) which are, in contrast to the other
used cell lines, replication permissive for adenoviral vectors.
To analyze the contribution of infection rate and promoter
strength to receptor expression we analyzed in parallel the
expression of AdCMVLacZ and AdRSVLuc in these cell lines
at di¡erent moi, 24 h post infection (Fig. 2). There is a non-
linear relationship between moi and the percentage of cells
with detectable L-galactosidase levels, and a linear relation-
ship between moi and luciferase activity in all cell lines, except
in mouse Ltk3 cells which fail to express either reporter gene.
The rank order of infectivity, as measured by percentage of
L-galactosidase expressing cells, and rank order of RSV pro-
moter strength, as measured by luciferase activity, di¡er with
the rank order for adenoviral-mediated dopamine receptor
expression of the cell lines. Relative dopamine receptor ex-
pression at 24 h, controlled for equal infectivity (75^90%)
and corrected for relative promoter strength in the di¡erent
cell lines, exhibits large di¡erences in relative expression be-
tween the examined cell lines (Fig. 6).
To explore whether the recombinant D2 and D4 expressing
adenoviruses can express the receptors in vivo we injected
AdRSVD2 and AdRSVD4.4 by themselves or in combination
with AdCMVLacZ (V2U107 pfu per injection (2^5 Wl) for
each virus) in caudate putamen and the third ventricle. Seven
days post injection expression of the dopamine receptors is
detected by in vitro autoradiography in the injected areas
(Fig. 5) and corresponds to the region stained for L-galacto-
sidase activity when co-injected with AdCMVLacZ. Expres-
sion of the receptors was higher than the corresponding non-
injected contralateral sites, but no di¡erences were observed
when only AdCMVLacZ or AdRSVLuc were injected. In
striatum AdRSVD2- and D4.4-mediated dopamine receptor
expression was measured by comparing the ROD of the in-
jected site was about 110% (D4.4) and 30% (D2) increased
compared to the contralateral site as measured by
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Fig. 5. Autoradiographic detection of D2 and D4 receptors ex-
pressed by AdRSVD2 and AdRSVD4, respectively, through stereo-
tactic delivery of these adenoviral expression vectors in rat brain.
The dopamine receptors were visualized by in vitro autoradiography
using [3H]spiperone at 7 days post infection. A: Autoradiographic
detection of [3H]spiperone binding sites in a coronal section through
rat brain infected with AdRSVD2 in right striatum. B: Autoradio-
graphic detection of [3H]spiperone binding sites in a coronal section
of rat brain infected with both AdRSVD4.4 and AdCMVLacZ on
the same site. C: Autoradiographic detection of [3H]spiperone bind-
ing sites in a coronal section of rat brain infected with AdRSVD4.4
in the right ventricle. D: The consecutive brain section shown in B
stained for L-galactosidase expression.
Fig. 6. Relative expression of D2 and D4 receptors and luciferase in di¡erent cell lines infected at 75^90% infection e⁄ciency with AdRSVD2
(A), AdRSVD4.4 (B) and AdRSVLuc (C) 24 h post infection. The relative expression of the receptors corrected for promoter-mediated contri-
bution (Bmax/relative luciferase activity (RLU)) is shown for D2 (D) and D4.4 (E).
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[3H]spiperone binding. Injection of the receptor expressing
viruses into the third ventricle resulted in a high [3H]spiperone
signal in the ependymal cell layer lining the ventricles with an
average 3.6-fold higher level of [3H]spiperone binding than
seen in striatum (Fig. 5).
4. Discussion
The data presented demonstrate that ¢rst generation re-
combinant adenoviruses are suitable vectors to mediate high
levels of dopamine D2 and D4 receptor expression in a wide
variety of established cell lines and in rat brain. The human
D2long and D4.4 receptors [27^29] were expressed from the
RSV-LTR promoter cloned into the E1a region of adenovirus
serotype 5. These replication-de¢cient recombinant viruses
were successfully grown in HEK293 cells at titers approaching
1011 pfu/ml. The viral stocks contained no detectable levels of
wild type virus as determined by both HeLa plaque assays
and PCR.
The pharmacological pro¢les and functional activity of the
dopamine receptors expressed by the recombinant adenovi-
ruses were tested in CHO-K1 cells. These cells have previously
been shown to mediate functional dopamine D2 and D4 re-
ceptor expression when stably transfected with expression vec-
tors using the RSV-LTR promoter [25]. The virally expressed
dopamine receptors display the appropriate pharmacological
pro¢le characterized by the low a⁄nity of raclopride and rel-
atively higher a⁄nity of clozapine for D4 receptors as com-
pared to D2 receptors (Table 1) [27]. In contrast to the D4
receptor expressing cells, the D2 expressing cells do not dis-
play high a⁄nity binding for either dopamine or quinpirole
(Table 1). However, both receptor subtypes expressed by the
adenoviral vector can almost completely reverse forskolin-
stimulated cAMP increases when stimulated by dopamine or
quinpirole (Fig. 1). This indicates that both receptors are
functional and the di¡erence in percentage of high a⁄nity
agonist binding sites may be due to the levels of expression
of the receptors in relation to the available pool of interacting
G proteins [30,31], indicating that the two receptors interact
preferentially with di¡erent G proteins.
Various established cell lines were infected with the re-
combinant adenoviral vectors at di¡erent moi for various
lengths of time to evaluate the in£uence of time and moi on
dopamine receptor expression. All cell lines tested that were
e⁄ciently infected by the recombinant adenovirus expressed
the dopamine receptors. Ltk3 cells could not be infected e⁄-
ciently with adenovirus. In general, it was observed that max-
imum expression for the dopamine receptors was reached
within 24 h post infection in the various cell lines, and the
levels of expression were proportional to the moi. Further,
expression levels stayed relatively constant after 24 h for the
duration of the culture to a maximum of 7 days. The duration
of culture post infection was determined by the ability to grow
without having to split the cells, and thus was directly deter-
mined by the cell doubling time. The cells continued to grow
normally after infection, although at the highest moi some cell
toxicity was observed. In absolute terms the somatomamma-
trophic cell line GH4-C1 and the neuroepithelioma SKNMC
expressed the highest levels of dopamine receptors. For the
D4 receptors the maximum recorded levels in GH4-C1 cells
were more than 10-fold higher than reported in any other
expression system used. The relatively constant levels of ex-
pression for the duration of culture suggests that dilution of
the expression vector through cell doubling is of minor in£u-
ence, possibly re£ecting the relatively long half-life of the re-
ceptors.
The recombinant adenoviral vector mediates good expres-
sion of the dopamine D2 and D4 receptors in both striatum
and ependymal cells lining the ventricles. In addition we were
able to express these two receptors in primary cultures of
anterior pituitary cells (data not shown). Similar ¢ndings
have recently been reported by Ikari et al. [18], who achieved
increased in vivo expression of D2 receptors in striatum, using
an adenoviral vector. This vector mediated a change in rota-
tional behavior after unilateral injection of the vector in stria-
tum, indicating that their vector is functionally active and can
be used to alter behavioral responses [19]. This vector of Ikari
et al. [18] employs the cytomegalovirus (CMV) immediately
early promoter enhancer rather than the RSV-LTR promoter
of our studies. In time course experiments they could achieve
maximum receptor expression in striatum of about 50% over
endogenous D2 expression in that region at day 3 post injec-
tion. The expression decreased to 20% at day 7 to undetect-
able after 3 weeks post injection. Our D2 expressing vector
achieved a 30% increase in expression of D2 receptors in
striatum at 7 days post injection, which is in agreement with
Umegaki et al. [19]. However, our D4 expressing vector medi-
ated levels of expression that were 110% over endogenous D2
levels in striatum. Whether this is inherent to the D4 receptor
or normal variation requires a comparative analysis study.
The in vivo time course studies done by Umegaki et al. [19]
suggest that maximum D2 receptor expression occurs rapidly
after infection, but contrary to our in vitro studies a rapid loss
in expression was also observed, possibly involving a combi-
nation of cellular immune responses, cytotoxicity [32,33] and
promoter silencing [34].
The di¡erence in expression levels between the cell lines can
be attributed to several factors, which include infection e⁄-
ciency and RSV-LTR promoter strength. Di¡erences in e⁄-
ciency of infection were most striking for the mouse Ltk3
cells, which apparently cannot be infected with adenovirus.
This cell line is known to use the employed viral promoters
from DNA transfection assays using expression constructs
with these promoters. Comparison of the expression of the
receptors at equivalent infection levels between di¡erent cell
lines still reveals large di¡erences in expression. In part these
di¡erences are due to di¡erences in strength at which the
RSV-LTR promoter is used in the di¡erent cell lines, as can
be seen from the di¡erences in expression of the reporter
vector AdRSVLuc. The SKNMC and COS-7 cells, in contrast
to the CHO-K1 cells, display very e⁄cient expression of
AdRSVLuc (Fig. 6). However, dopamine receptor expression
levels in the di¡erent cell lines do not correlate with the ex-
pression of the luciferase reporter vector. When the dopamine
receptor expression is adjusted for infection e⁄ciency and
corrected for promoter strength, di¡erences in dopamine re-
ceptor expression of more than two orders of magnitude can
still be observed between the di¡erent cell lines (Fig. 6). These
analyses indicate that the high levels of dopamine receptor
expression in SKNMC cells is strongly determined by the
promoter strength, while high levels of expression in GH4-
C1 and CHO-K1 cells are more strongly determined by
post-transcriptional regulation. These data indicate that fac-
tors other than infection e⁄ciency and promoter strength play
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an important role in the expression of these receptors. Re-
cently, much progress has been made in the understanding
of how agonist-mediated processes modulate receptor synthe-
sis, internalization, sequestration and down-regulation, but
little is known about how cells regulate their steady-state lev-
els of expression. Potential factors underlying these di¡erences
may be related to which signal transduction pathways the
receptors are coupled to, and mechanisms that control ago-
nist-mediated receptor regulation. However, it should be
noted that both the D2 and D4 receptor show very similar
pro¢les in expression levels in the di¡erent cell lines, despite
observed di¡erences in functional coupling between the two
receptors [23]. Cellular factors that modulate RNA stability,
the e⁄ciency of translation and transport and turnover of
non-stimulated dopamine receptors have not been described,
but appear to be strong determinants for cell-speci¢c expres-
sion. This adenovirus-mediated expression system provides a
valuable resource for the examination of such processes.
In conclusion, recombinant adenoviral vectors are excellent
vehicles to mediate high expression of D2 and D4 receptors in
vitro and in vivo. Expression of the receptors is, as expected,
dependent on factors that determine viral tropism as well as
the strength of the employed promoter. Most importantly,
these studies demonstrate that steady state levels of receptor
expression are strongly dependent on post-transcriptional
processes which can contribute to large di¡erences, up to
two orders of magnitude, in receptor expression in di¡erent
cell types.
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